These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11897602)

  • 21. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
    Lofland D; Difuntorum S; Waller A; Clements JM; Weaver MK; Karlowsky JA; Johnson K
    J Antimicrob Chemother; 2004 Apr; 53(4):664-8. PubMed ID: 14973152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.
    Jones RN; Rhomberg PR
    J Antimicrob Chemother; 2003 Jan; 51(1):157-61. PubMed ID: 12493802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors.
    Lee SJ; Lee SJ; Lee SK; Yoon HJ; Lee HH; Kim KK; Lee BJ; Lee BI; Suh SW
    Acta Crystallogr D Biol Crystallogr; 2012 Jul; 68(Pt 7):784-93. PubMed ID: 22751663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel approaches to antimicrobial therapy: peptide deformylase.
    Waller AS; Clements JM
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):785-92. PubMed ID: 12630299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of 4'-((5-benzylidene-2,4-dioxothiazolidin-3-yl)methyl)biphenyl-2-carbonitrile analogs as bacterial peptide deformylase inhibitors.
    Khan FA; Patil RH; Shinde DB; Sangshetti JN
    Chem Biol Drug Des; 2016 Dec; 88(6):938-944. PubMed ID: 27401234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
    Fritsche TR; Moet GJ; Jones RN
    Clin Microbiol Infect; 2004 Sep; 10(9):857-60. PubMed ID: 15355422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents.
    Jain R; Chen D; White RJ; Patel DV; Yuan Z
    Curr Med Chem; 2005; 12(14):1607-21. PubMed ID: 16022661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Peptide-deformylase inhibitors, a new class of antibiotics].
    Dubreuil L
    Presse Med; 2002 Nov; 31(38):1810-2. PubMed ID: 12497724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
    Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
    Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
    Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ; Beach ML; Jones RN
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.
    Hackbarth CJ; Chen DZ; Lewis JG; Clark K; Mangold JB; Cramer JA; Margolis PS; Wang W; Koehn J; Wu C; Lopez S; Withers G; Gu H; Dunn E; Kulathila R; Pan SH; Porter WL; Jacobs J; Trias J; Patel DV; Weidmann B; White RJ; Yuan Z
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2752-64. PubMed ID: 12183225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species.
    Smith KJ; Petit CM; Aubart K; Smyth M; McManus E; Jones J; Fosberry A; Lewis C; Lonetto M; Christensen SB
    Protein Sci; 2003 Feb; 12(2):349-60. PubMed ID: 12538898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.